Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9

Reference

• BLAKE, J. A., PRITCHARD, M., DING, S., SMITH, G. C., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1996, Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Letters, 397, 210–214.
   PubMed Web of Science ®Google Scholar
• CHUN, Y. J., SHIMADA, T. and GUENGERICH, F. P., 1996, Construction of a human cytochrome P450 1A1: rat NADPH-cytochrome P450 reductase fusion protein cDNA and expression in Escherichia coli, purification, and catalytic properties of the enzyme in bacterial cells and after purification. Archives of Biochemistry and Biophysics, 330, 48–58.
   PubMed Web of Science ®Google Scholar
• CUTTLE, L., MUNNS, A. J., HOGG, N. A., SCOTT, J. R., HOOPER, W. D., DICKINSON, R. G. and GILLAM, E. M., 2000, Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug—protein adduct formation. Drug Metabolism and Disposition, 28, 945–950.
   PubMed Web of Science ®Google Scholar
• DAI, D., ZELDIN, D. C., BLAISDELL, J. A., CHANAS, B., COULTER, S. J., GHANAYEM, B. I. and GOLDSTEIN, J. A., 2001, Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 11, 597–607.
   PubMedGoogle Scholar
• DONG, J. and PORTER, T. D., 1996, Coexpression of mammalian cytochrome P450 and reductase in Escherichia coli. Archives of Biochemistry and Biophysics, 327, 254–259.
   PubMed Web of Science ®Google Scholar
• FISHER, C. W., SHET, M. S. and ESTABROOK, R. W., 1996, Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. Methods in Enzymology, 272, 15–25.
   PubMed Web of Science ®Google Scholar
• FISHER, C. W., SHET, M. S., CAUDLE, D. L., MARTIN-WIXTROM, C. A. and ESTABROOK, R. W., 1992, High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase fiavoprotein. Proceedings of the National Academy of Sciences, USA, 89, 10817–10821.
   Google Scholar
• FISSLTHALER, B., Popp, R., KISS, L., POTENTE, M., HARDER, D. R., FLEMING, I. and BUSSE, R., 1999, Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 401, 493–497.
   PubMed Web of Science ®Google Scholar
• FUJITA, K. and KAMATAKI, T., 2002, Genetically engineered bacterial cells co-expressing human cytochrome p450 reductase: prediction of metabolism and toxicity of drugs in humans. Drug Metabolism and Pharmacokinetics, 17, 1–22.
   PubMedGoogle Scholar
• GILLAM, E. M., BABA, T., KIM, B. R., OHMORI, S. and GUENGERICH, F. P., 1993, Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Archives of Biochemistry and Biophysics, 305, 123–131.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 2001, Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chemical Research in Toxicology, 14, 611–650.
   PubMed Web of Science ®Google Scholar
• IWATA, H., FUJITA, K., KUSHIDA, H., SUZUKI, A., KONNO, Y., NAKAMURA, K., FUJINO, A. and KAMATAKI, T., 1998, High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemical Pharmacology, 55, 1315–1325.
   PubMed Web of Science ®Google Scholar
• MCGINNITY, D. F., GRIFFIN, S. J., MOODY, G. C., VOICE, M., HANLON, S., FRIEDBERG, T. and RILEY, R. J., 1999, Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metabolism and Disposition, 27, 1017–1023.
   PubMed Web of Science ®Google Scholar
• MINERS, J. 0. and BIRKETT, D. J., 1998, Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45, 525–538.
   Google Scholar
• MINERS, J. 0., COULTER, S., BIRKETT, D. J. and GOLDSTEIN, J. A., 2000, Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics, 10, 267–270.
   Google Scholar
• MINERS, J. 0., REES, D. L., VALENTE, L., VERONESE, M. E. and BIRKETT, D. J., 1995, Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. Journal of Pharmacology and Experimental Therapeutics, 272, 1076–1081.
   Google Scholar
• MURAKAMI, H., YABUSAKI, Y., SAKAKI, T., SHIBATA, M. and OHKAWA, H., 1987, A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450c and NADPH-cytochrome P450 reductase. DNA, 6, 189–197.
   PubMedGoogle Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• ONG, C. E., COULTER, S., BIRKETT, D. J., BHASKER, C. R. and MINERS, J. 0., 2000, The xenobiotic inhibitor profile of cytochrome P4502C8. British Journal of Clinical Pharmacology, 50, 573–580. PARIKH, A., GILLAM, E. M. and GUENGERICH, F. P., 1997, Drug metabolism by Escherichia coli expressing human cytochromes P450. Nature Biotechnology, 15, 784–788.
   Google Scholar
• PARIKH, A. and GUENGERICH, F. P., 1997, Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein. Protein Expression and Purification, 9, 346–354.
   PubMed Web of Science ®Google Scholar
• PRITCHARD, M. P., GLANCEY, M. J., BLAKE, J. A., GILHAM, D. E., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1998, Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8, 33–42.
   PubMedGoogle Scholar
• RENDIC, S., 2002, Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews, 34, 83–448.
   PubMed Web of Science ®Google Scholar
• RICHARDSON, T. H., JUNG, F., GRIFFIN, K. J., WESTER, M., RAUCY, J. L., KEMPER, B., BORNHEIM, L. M., HASSETT, C., OMIECINSKI, C. J. and JOHNSON, E. F., 1995, A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Archives of Biochemistry and Biophysics, 323, 87–96.
   PubMed Web of Science ®Google Scholar
• SANDHU, P., BABA, T. and GUENGERICH, F. P., 1993, Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Archives of Biochemistry and Biophysics, 306, 443–450.
   PubMed Web of Science ®Google Scholar
• SHEN, A. L., PORTER, T. D., WILSON, T. E. and KASPER, C. B., 1989, Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. Journal of Biological Chemistry, 264, 7584–7589.
   PubMed Web of Science ®Google Scholar
• SHET, M. S., FISHER, C. W., ARLOTTO, M. P., SHACKLETON, C. H., HOLMANS, P. L., MARTIN-WIXTROM, C. A., SAEKI, Y. and ESTABROOK, R. W., 1994, Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A and rat NADPH-P450 reductase. Archives of Biochemistry and Biophysics, 311, 402–417.
   Google Scholar
• SHET, M. S., FISHER, C. W., HOLMANS, P. L. and ESTABROOK, R. W., 1993, Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proceedings of the National Academy of Sciences, USA, 90, 11748–11752.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., TSUMURA, F., GILLAM, E. M., GUENGERICH, F. P. and INouE, K., 2000, Roles of NADPH-P450 reductase in the 0-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 IBI variants in Escherichia coli. Protein Expression and Purification, 20, 73–80.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L., COURT, M. H., HARMATZ, J. S., CRESPI, C. L. and GREENBLATT, D. J., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493–1504.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., NAKAJIMA, M., NAKAMURA, M., ASAHI, S., SHIMADA, N., GILLAM, E. M., GUENGERICH, F. P., SHIMADA, T. and YOKOI, T., 1999, Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Drug Metabolism and Disposition, 27, 999–1004.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., NAKAMURA, M., KOMATSU, T., OHYAMA, K., HATANAKA, N., ASAHI, S., SHIMADA, N., GUENGERICH, F. P., SHIMADA, T., NAKAJIMA, M. and YOKOI, T., 2002, Roles of NADPH-P450 reductase and apo- and holo-cytochrome b(5) on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression and Purification, 24, 329–337.
   PubMed Web of Science ®Google Scholar
• YASUKOCHI, Y. and MASTERS, B. S., 1976, Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry, 251, 5337–5344.
   PubMed Web of Science ®Google Scholar
• YON, J. and FRIED, M., 1989, Precise gene fusion by PCR. Nucleic Acids Research, 17, 4895.
   PubMed Web of Science ®Google Scholar
• ZELDIN, D. C., DuBois, R. N., FALCK, J. R. and CAPDEVILA, J. H., 1995, Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Archives of Biochemistry and Biophysics, 322, 76–86.
   PubMed Web of Science ®Google Scholar